The FDA approved cemdisiran (Livsayis; Regeneron), a subcutaneous siRNA dosed every 3 months, for AChR-positive generalized myasthenia gravis.
Florin Draica of Shionogi explains the 72-hour PEP window for ensitrelvir, breakthrough infection data, and which patients to ...
New York hepatitis B experts say screening gaps and weekly monitoring demands could limit who benefits from the first functional cure therapy.
Infectious disease and urology clinicians described unclear treatment goals, infusion limits, and access barriers for newer ...
CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic ...
Obinutuzumab (Gazyva) led to complete remission of proteinuria in more patients than tacrolimus did, according to the FDA.
An oral SERD plus everolimus cut the risk of progression or death by 62% in ESR1-mutated advanced breast cancer.
Nearly 90% of patients in the MINT trial tapered prednisone to 5 mg/day or less, with no significant safety concerns seen to ...
Cardiologists and pharmacy leaders explained how team-based clinics and standardized paperwork are speeding obstructive HCM ...
New ACACIA-HCM analyses at HCMS 2026 add imaging and quality-of-life data as Cytokinetics readies an FDA filing in nonobstructive HCM.
Once weekly ribupatide, a dual GIP/GLP-1 receptor agonist, led to significantly greater weight loss than placebo at 48 weeks, ...
The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.